Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Completed · Phase 2

Conditions studied: Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors

In brief

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Key facts

Study ID

NCT01461538

Run by

Seagen Inc.

People needed

84

Starts

2011-10-01

Expected to finish

2014-12-01

Last updated by the study team

2016-03-04

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy
• Have failed, refused, or have been deemed ineligible for standard therapy
• Measurable disease
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70

You may not qualify if…

• Primary diagnosis of lymphoma or central nervous system (CNS) malignancy
• History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years
• Evidence of active cerebral/meningeal disease

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• City of Hope — Duarte, California, United States
• PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists — Oxnard, California, United States
• Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado, United States
• Mayo Clinic Cancer Center — Jacksonville, Florida, United States
• Ocala Oncology Center — Ocala, Florida, United States
• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Minnesota Oncology Hematology P.A. — Minneapolis, Minnesota, United States
• New York Oncology Hematology, P.C. — Albany, New York, United States
• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• Willamette Valley Cancer and Research / USOR — Eugene, Oregon, United States
• Northwest Cancer Specialists, P.C. — Tulatin, Oregon, United States
• St. Francis Hospital — Greenville, South Carolina, United States
• Texas Oncology - Bedford — Bedford, Texas, United States
• Texas Oncology - Medical City Dallas — Dallas, Texas, United States
• Texas Oncology - Dallas Presbyterian — Dallas, Texas, United States
• Texas Oncology Denton South — Denton, Texas, United States
• Texas Oncology - Fort Worth 12th Avenue — Fort Worth, Texas, United States
• MD Anderson Cancer Center / University of Texas — Houston, Texas, United States
• MD Anderson Cancer Center Leukemia Group — Houston, Texas, United States
• Texas Oncology - Central Austin Cancer Center — Round Rock, Texas, United States
• Cancer Centers of South Texas - HOAST — San Antonio, Texas, United States
• Texas Oncology - Waco — Waco, Texas, United States
• Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care — Blacksburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.